N/A N=39 Impact of a Low-Carbohydrate Diet in Pediatric Type 1 Diabetes
Type 1 Diabetes
Primary: Change in HbA1c — 0.4; 0.3; -0.2 percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=337 Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)
Atopic Dermatitis
Primary: Percentage of Participants Who Had at Least a 2-grade Reduction From Baseline at Week 6 in the Investigator Global Assessment (IGA) Scale and Had an IGA at Week 6 That…
N/A N=10 Move Together Boston Feasibility Pilot (Sit Less, Move More App for Black Breast Cancer Survivors & At-Risk Relatives)
Breast Cancer Survivor · Breast Cancer · Fitness Trackers
Primary: System Usability Scale (SUS) Score — 72 units on a scale
Phase 4 N=23 Study of the Safety and Efficacy of Botox in Bruxism
Bruxism
Primary: Bruxism Questionnaire Baseline and at Week 4 — 19.4; 16.1; 24.0; 24.0 units on a scale — p=0.0394
N/A N=60 Social Media HIV Prevention Intervention for High Risk Rural Women
HIV/AIDS
Primary: Facebook Enrollment — 15; 15 Participants
N/A N=24 Patient Acceptance and Preference Among Screening Modalities for Detection of Barrett's Esophagus
Barrett Esophagus · GERD
Primary: 7 Days Post-EGD Impact of Events Score (IES) — 1.42; 1.21; 0 units on a scale
Phase 4 N=45 Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD
COPD
Primary: DPI Responder Analysis in Patients With Suboptimal PIF (<60 L/Min) — 2; 1 Number of subject test days — p=0.33
Phase 2 N=36 PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer
Prostate Cancer
Primary: Diagnostic Accuracy of PSMA PET — 100; 74 percentage
N/A N=12 Standardized Evaluation of Subcutaneous Glucose Monitoring Systems Under Routine Environmental Conditions
Diabetes Mellitus, Type 1
Primary: Percentage of Test-to-Reference Measurement Pairs With an Absolute Relative Difference (ARD) ≤15% — 73.2; 56.1; 52.0 Percentage of sensor values
Phase 2 N=98 A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) (Safety Run-In Only) — 0; 1 Participants
Phase 2 N=7 IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer
FIGO Stage III and IV Ovarian Cancer · FIGO Stage III and IV Fallopian Tube Cancer · FIGO Stage III Primary Peritoneal Cancer
Primary: Progression Free Survival — 50; 100 Percentage of PFS
Phase 2 N=17 Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
Multiple Indications Cancer
Primary: Number of Participants Who Received Dasatinib Treatment — 1; 16 Participants
N/A N=600 Reducing HIV Vulnerability Through A Multilevel Life Skills Intervention For Adolescent Men
HIV Infections · Sexually Transmitted Diseases · Sexual Behavior
Primary: Confidence to Engage in HIV Prevention Behaviors When Engaging in Receptive Anal Sex Over Time — 1.72; 1.71; 1.73; 1.72 units on a scale
N/A N=164 Class II Correction Study Using the Invisalign System
Malocclusion
Primary: Rate of Tooth Movement at the End of Class II Correction. — .44 mm/month
N/A N=34 Glasses for Adolescent Delayed Sleep-Wake Phase Disorder
Delayed Sleep-Wake Phase Disorder
Primary: Change in School Night Sleep Onset Time — 0.4; 0.6 hours